Page last updated: 2024-11-06

ly 178210

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

LY 178210: 5-hydroxytryptamine receptor agonist; structure given in first source; LY 228729 is the (-)-isomer; LY 228730 is the (+)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID60845
CHEMBL ID296753
SCHEMBL ID6364891
MeSH IDM0182279

Synonyms (17)

Synonym
ly-228730
benz(cd)indole-6-carboxamide, 4-(dipropylamino)-1,3,4,5-tetrahydro-
114943-19-0
ly-178210
4-(dipropylamino)-1,3,4,5-tetrahydrobenz(cd)indole-6-carboxamide
ly 228729
ly 178210
CHEMBL296753 ,
L004509
4-(dipropylamino)-1,3,4,5-tetrahydrobenzo[cd]indole-6-carboxamide
SCHEMBL6364891
4-(di-n-propyl)amino-6-aminocarbonyl-1,3,4,5-tetrahydrobenz[cd]indole
YTOJFUORFUYGSV-UHFFFAOYSA-N
bdbm50227633
4-(dipropylamino)-1,3,4,5-tetrahydrobenzo[cd]indole-6-carboximidic acid
100561-24-8
DTXSID20905583

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" Collectively, these results indicate that LY228729 is potent 5-HT1A agonist with bioavailability properties sufficient for clinical evaluation and with efficacy in preclinical models of anxiety, sexual disorders and motion sickness."( Preclinical studies on LY228729: a potent and selective serotonin1A agonist.
Benvenga, MJ; Calligaro, DO; Flaugh, ME; Foreman, MM; Fuller, RW; Leander, JD; Lucot, JB; Nelson, DL; Swanson, SP; Wong, DT, 1993
)
0.29

Dosage Studied

ExcerptRelevanceReference
"LY228729 [(-)-4(dipropylamino)-1,3,4,5-tetrahydrobenz-[c,d]indole-6-carboxa mide]], an agonist at the 5-HT1A subtype of 5-HT receptor, was studied as an antiemetic in pigeons dosed with a highly emetic oncolytic agent, cyclophosphamide."( Effects of a 5-HT1A receptor agonist on acute and delayed cyclophosphamide-induced vomiting.
Leander, JD; Wolff, MC, 1997
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID3665Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes1988Journal of medicinal chemistry, Sep, Volume: 31, Issue:9
6-substituted 1,3,4,5-tetrahydrobenz[cd]indol-4-amines: potent serotonin agonists.
AID5060Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes1988Journal of medicinal chemistry, Sep, Volume: 31, Issue:9
6-substituted 1,3,4,5-tetrahydrobenz[cd]indol-4-amines: potent serotonin agonists.
AID173458Effect on 5HIAA (5-hydroxyindoleacetic acid) concentration in hypothalamus as an index of serotonin turnover in male Wistar rats expressed as percent of control1988Journal of medicinal chemistry, Sep, Volume: 31, Issue:9
6-substituted 1,3,4,5-tetrahydrobenz[cd]indol-4-amines: potent serotonin agonists.
AID174302In vivo serum corticosterone concentration in male Wistar rats after injecting 0.3 mg/kg of compound subcutaneously1988Journal of medicinal chemistry, Sep, Volume: 31, Issue:9
6-substituted 1,3,4,5-tetrahydrobenz[cd]indol-4-amines: potent serotonin agonists.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (10.00)18.7374
1990's7 (70.00)18.2507
2000's2 (20.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.66

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.66 (24.57)
Research Supply Index2.48 (2.92)
Research Growth Index5.15 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.66)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]